Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PAveMenT: Palbociclib and Avelumab in Metastatic AR+ TNBC
NCT04360941Phase 1Active, not recruiting
- Sponsor
- Royal Marsden NHS Foundation Trust
- Start
- Aug 2020
- Primary completion
- Jul 2027
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of palbociclib and avelumab in breast cancer and triple-negative breast cancer (TNBC), sponsored by Royal Marsden NHS Foundation Trust. Primary endpoints: Maximum Tolerated Dose at 18 months and Objective Response Rate at 24 months. Started Aug 2020; status: active, not recruiting.
02
Drugs
palbociclibavelumab
03
Conditions
breast cancertriple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT04360941.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04360941.